Glenn Lesser to Central Nervous System Neoplasms
This is a "connection" page, showing publications Glenn Lesser has written about Central Nervous System Neoplasms.
Connection Strength
2.364
-
Strowd RE, Swett K, Harmon M, Carter AF, Pop-Vicas A, Chan M, Tatter SB, Ellis T, Blevins M, High K, Lesser GJ. Influenza vaccine immunogenicity in patients with primary central nervous system malignancy. Neuro Oncol. 2014 Dec; 16(12):1639-44.
Score: 0.479
-
Strowd RE, Knovich MA, Lesser GJ. The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies. Curr Treat Options Oncol. 2012 Dec; 13(4):451-64.
Score: 0.436
-
Renfrow JJ, Detroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol. 2012 May; 107(3):659-63.
Score: 0.411
-
Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 08; 76(10):929-30.
Score: 0.387
-
Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009 Aug; 10(3-4):231-42.
Score: 0.339
-
Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004 Dec; 5(6):511-7.
Score: 0.250
-
Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 01; 10(17):5643-6.
Score: 0.062